Tonix Pharmaceuticals Announces Enrollment of Phase 3 RELIEF Trial of TNX-102 SL for Management of Fibromyalgia is Ahead of Schedule June 29, 2020 • 7:00 AM EDT
Tonix Pharmaceuticals Announces Results from Preclinical Study of TNX-1700 Presented in a Poster at AACR Virtual Annual Meeting 2020 June 22, 2020 • 9:00 AM EDT
Tonix Pharmaceuticals and Southern Research Announce Expansion of COVID-19 Vaccine Collaboration June 18, 2020 • 7:00 AM EDT
Tonix Pharmaceuticals Announces that Results from Preclinical Studies of TNX-1700 Will be Presented in a Poster at the AACR Virtual Annual Meeting 2020 June 17, 2020 • 7:00 AM EDT
Tonix Pharmaceuticals Announces Acquisition of Non-Addictive Migraine and Pain Treatment Programs from Trigemina and Assumption of License June 11, 2020 • 2:43 PM EDT
Tonix Pharmaceuticals Announces Appointment of Richard H. Bagger to Board of Directors June 10, 2020 • 7:00 AM EDT
Tonix Pharmaceuticals to Participate in Two June Virtual Investor Conferences June 3, 2020 • 7:00 AM EDT
Tonix Pharmaceuticals Announces FUJIFILM Diosynth Biotechnologies to be Manufacturing Partner for COVID-19 Vaccine Candidate TNX-1800 June 1, 2020 • 7:00 AM EDT
Tonix Pharmaceuticals Posted Results from Pharmacokinetic Analyses of TNX-102 SL and TNX-601 CR in Advance of Virtual Poster Presentations at the American Society of Clinical Psychopharmacology May 21, 2020 • 7:00 AM EDT
Tonix Pharmaceuticals Announces Appointment of Herbert Harris, M.D., Ph.D., as Executive Vice President, Translational Medicine May 19, 2020 • 7:00 AM EDT
